NICE recommends breast cancer drug pertuzumab

NICE recommends breast cancer drug pertuzumab

The National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s Perjeta (pertuzumab) by the NHS to treat early HER2-positive breast cancer, which has spread to lymph nodes.

The recommendation covers use of pertuzumab along with trastuzumab and chemotherapy in patients who have had surgery for their breast cancer but the cancer already spread to their lymph nodes.

It comes after the Swiss healthcare company Roche agreed to offer an improved discount for the drug.

NICE previously stated the cost effectiveness estimates of the drug were too high, considering Roche’s predictions of overall survival in patients.

In its latest guidance, NICE noted that pertuzumab in combination with trastuzumab and chemotherapy significantly increased the proportion of patients whose disease didn’t spread in clinical studies.

Meindert Boysen, director of the Centre for Health Technology Assessment at NICE said: “We’re pleased that we’ve been able to work with the company to address the uncertainties of pertuzumab as a treatment for early HER2-positive breast cancer.

“Their response means that people who have a high risk of their cancer returning now have a new treatment option that could reduce the risk of that happening.”

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho